This is attributed to ER− breast cancer cell lines having suppressed levels of PP2A activity in comparison to ER+ breast cancer cell lines thus having a higher sensitivity to a PP2A activator such as FTY720. The gene discussed is PTPA; the disease is breast carcinoma.